LCTX

LCTX Other Income/Expenses (Net)

-$10.54MTTM · USD

Period ending:

LCTX FY Other Income/Expenses (Net)USD
LCTX FY Other Income/Expenses (Net)1992-06-30: $700.00K1993-06-30: $400.00K1994-06-30: $1.10M1995-06-30: $200.00K1996-06-30: $1.30M1998-06-30: $650.00K1998-12-31: $400.00K1999-12-31: $279.83K2000-12-31: $165.26K2001-12-31: $114.34K2002-12-31: -$810.30K2003-12-31: -$134.72K2004-12-31: -$1.07M2005-12-31: -$55.84K2006-12-31: -$112.76K2007-12-31: -$215.85K2008-12-31: -$958.26K2009-12-31: -$1.62M2010-12-31: -$1.33M2011-12-31: $212.82K2012-12-31: -$305.18K2013-12-31: -$203.82K2014-12-31: -$472.14K2015-12-31: $3.16M2016-12-31: $77.59M2017-12-31: $15.61M2018-12-31: -$5.34M2019-12-31: $19.64M2020-12-31: $4.52M2021-12-31: $5.94M2022-12-31: -$3.29M2023-12-31: $1.45M2024-12-31: $2.90M2025-12-31: -$46.87M$77.59M-$46.87M
1992-06-302025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

LCTX other income/expenses (net) history

Net other income and expenses outside core operations. The available annual fiscal periods series contains 34 observations from Jun 30, 1992 to Dec 31, 2025.

Lineage Cell Therapeutics, Inc. Common Stock Other Income/Expenses (Net) — Annual fiscal periods (USD)
Period endingOther Income/Expenses (Net) (USD)
-46,868,000
2,896,000
1,451,000
-3,292,000
5,941,000
4,523,000
19,642,000
-5,335,000
15,613,000
77,588,000
3,159,000
-472,137
-203,821
-305,183
212,821
-1,332,485
-1,624,233
-958,263
-215,853
-112,757
-55,840
-1,067,032
-134,716
-810,303
114,344
165,256
279,827
400,000
650,000
1,300,000
200,000
1,100,000
400,000
700,000

Compare other income/expenses (net)

All LCTX financial metrics · LCTX stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.